Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently reported positive clinical data with VX-135 (formerly ALS-2200, an anti-HCV nucleotide analog), demonstrates the broad capabilities of the Alios discovery platform. We are currently utilizing this platform to screen against several infectious diseases with high unmet medical needs."

Alios has built its drug discovery engine based on its core competencies in nucleoside synthetic chemistry, including prodrug chemistry, and a breadth and depth of virology expertise built over decades in the antiviral field. The Alios platform has been utilized to create a portfolio of antiviral drug candidates against multiple viruses including HCV, RSV, picornavirus (rhinovirus), and norovirus. In addition, the company is selectively pursuing non-nucleoside drug discovery in areas where combination regimens may be particularly useful.


'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/9/2016)... BEACH GARDENS, Fla. , March 9, 2016 ... identity management authentication and enrollment solutions, today announced ... DigitalPersona ® Altus multi-factor authentication ... IT and InfoSec managers to step-up security where ... Washington, DC . ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... , ... May 25, 2016 , ... WEDI, the nation’s ... exchange, today announced that Charles W. Stellar has been named by the WEDI Board ... since January 2016. As an executive leader with more than 35 years of experience ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... 2016 Oxitec CEO Hadyn Parry ... 10:15 a.m. ET before the United States House Committee on ... can play in controlling the spread of the Aedes ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... self-limiting gene. Trials in Brazil , ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
Breaking Biology Technology: